Spectrum Pharmaceuticals, Inc. (SPPI)

Spectrum Pharmaceuticals will tend to outperform S&P 500 due to increasing sales trends from Zevalin and possible approval of Fusilev. Combined sales from the two have the potential to reach approx. 400M in US. Assuming they reach 200M it would be a substantial gain in market share and approx. 10 fold increase in revenue over the prior year.
Additionally there may be some news and milestone payments received for Apaziquone and interim results from their ongoing PIII. Spectrum should receive milestone payments at the completion of PIII trial enrollment sometime in the 1H of 2010.
Additional licensing revenue for other compounds in their pipeline is also possible.
12 month price target for SPPI is approx. $12 which will be much larger than S&P 500 return at low to medium risk.

Cheap stock, good revenue and evaluations

a lot cash on hand with no debt. many drugs in the pipeline ready to be approve. any good news will launch this stock over $10.

just a hunch

Been beat up more than sufficiently for a bio with a good pipeline, increasing revenues, positive cash flow. Their bladder cancer drug candidate hold promise and is in phase 3. I expect SPPI will be a hot stock again in 2010.

Good drugs, much good stuff in the pipeline; underpriced at $4 and change.

Market value $200 million with cash of $150 million. Two approved drugs with potential sales of $200 million. A phase 3 bladder cancer drug partnered with Allergan while SPPI retain Asia rights. 8 early stage drugs also in pipeline.
They raised $80 million in last few months at average price of $7.

Perchè spectrum appare un'azienda sana senza debiti con alcune potenzialità di farmaci in sviluppo e commercio

Small cap drug maker has a lot of cash, two revenue-generating drugs, and a deep pipeline.

waiting for their stomach cancer drug with allergen

10/07

good pipeline, Coming FDA approval, no debt, 158 million in cash, possible buy-out

85percent chance approval

Favorable outcome most likely on the next FDA decision coming October. Anticipating significant PPS movement upward before announcement. Current retracement offers good entry point.

good pick!

SELL the NEWS! Spectrum Pharmacuticals edged up the last two weeks in anticipation of an FDA approval to expand the use of it's core product Zevalin to non-Hodgkin’s lymphoma, a blood cancer. Previously it was approved for tumors that didn't respond to other treatments. As such, the low medical and market potential for Zevalin was decaying and Spectrum was net negative on their revenue stream. The new potential should help with this. While FDA approval was not on the calendar until Monday, the Monday holiday and the fact this was a drug extension, allowed the FDA to give an early node. Spectrum shares had drifted up to below $10 on the announcement, and quickly popped DOWN!

The market for Zevalin with it's new approval still didn't rate the $10 PPS for Spectrum. See my blog with more details. Spectrum does have other drugs in the pipeline. Mr. Market's speculation of driving up a biopharmaceutical pre-news and dropping it after is rather common on companies with existing product (BDSI, VITA). Not every new drug will have the market opportunity to quadruple a companies share price. I suspect Spectrum will get some of the PPS back over time. The new market should hold their revenue stream or maybe even make them an attractive buyout since the big players are constantly looking for smaller fish to keep their coffers fresh as patents expire. I'm still holding, but wish my itchy trigger had fired at $10 and bought back later. The game of Pharma is a full time job and only the best can swing trade it, and many of them miss the mark.

good company (more importantly good catalyst's in the near future) featuring a major profit making possibility. this is a great long wager, but an even better mid term one.

Best Bio Bets

2 approved drugs on market, 2 upcoming FDA decisions, $106 million cash in bank, little debt, strong commercial team, 341$ million deal with allergan for potential blockbuster drug, buyout target over next 6-24 months, undervalued